NASDAQ:APENApollo Endosurgery Stock Price, Forecast & News

Apollo Endosurgery's stock was trading at $2.0650 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APEN stock has decreased by 15.3% and is now trading at $1.75. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Apollo Endosurgery.

Apollo Endosurgery is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Apollo Endosurgery.

Apollo Endosurgery Inc (NASDAQ:APEN) issued its earnings results on Monday, May, 4th. The biotechnology company reported ($0.49) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.49). The biotechnology company had revenue of $10.72 million for the quarter, compared to analyst estimates of $9.07 million. Apollo Endosurgery had a negative return on equity of 565.93% and a negative net margin of 72.34%. View Apollo Endosurgery's earnings history.

1 Wall Street analysts have issued twelve-month target prices for Apollo Endosurgery's shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate Apollo Endosurgery's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 14.3% from the stock's current price. View analysts' price targets for Apollo Endosurgery.

Headlines about APEN stock have trended negative recently, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Apollo Endosurgery earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutApollo Endosurgery.

Apollo Endosurgery saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 177,900 shares, a decline of 10.0% from the April 30th total of 197,600 shares. Based on an average trading volume of 12,500 shares, the days-to-cover ratio is currently 14.2 days. Approximately 1.4% of the shares of the company are short sold. View Apollo Endosurgery's Current Options Chain.

Some companies that are related to Apollo Endosurgery include RenovaCare (RCAR), Restoration Robotics (HAIR), BeyondAirInc . (XAIR), T2 Biosystems (TTOO), PAVmed (PAVM), Spectral Medical (EDTXF), Venus Concept (VERO), SANUWAVE Health (SNWV), BRAINSWAY LTD/S (BWAY), AIT Therapeutics (AITB), Pro-Dex (PDEX), Nephros (NEPH), Nephros (NEPHD), Sensus Healthcare (SRTS) and STRATA Skin Sciences (SSKN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Tonix Pharmaceuticals (TNXP), Second Sight Medical Products (EYES), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), Novavax (NVAX), Onconova Therapeutics (ONTX) and Opko Health (OPK).

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

Apollo Endosurgery's stock is owned by a variety of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (7.97%), Gagnon Securities LLC (4.79%), Prosight Management LP (1.60%), Falcon Point Capital LLC (0.17%) and Private Advisors LLC (0.10%). Company insiders that own Apollo Endosurgery stock include Matthew S Crawford, Stefanie L Cavanaugh, Stonepine Capital, LP and Todd Newton. View institutional ownership trends for Apollo Endosurgery.

APEN stock was sold by a variety of institutional investors in the last quarter, including Falcon Point Capital LLC. View insider buying and selling activity for Apollo Endosurgery.

APEN stock was acquired by a variety of institutional investors in the last quarter, including Prosight Management LP, Stonepine Capital Management LLC, Private Advisors LLC, and Gagnon Securities LLC. Company insiders that have bought Apollo Endosurgery stock in the last two years include Matthew S Crawford, Stefanie L Cavanaugh, Stonepine Capital, LP, and Todd Newton. View insider buying and selling activity for Apollo Endosurgery.

Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APEN stock can currently be purchased for approximately $1.75.

Apollo Endosurgery has a market capitalization of $36.98 million and generates $50.71 million in revenue each year. The biotechnology company earns $-27,430,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis. Apollo Endosurgery employs 215 workers across the globe.

The official website for Apollo Endosurgery is www.apolloendo.com.

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]